News

Biospace || Paradigm4 Joins the Tetra Partner Network to Leverage Tetra Data into High-performing Analytical Computing Applications for Pharmaceutical Customers

TetraScience, the R&D Data Cloud company, announced today that Paradigm4, an integrated scientific data analytics company, has joined the Tetra Partner Network (TPN) so that pharmaceutical customers can accelerate research decision-making using Tetra Data as a foundation for analytical computing.

whitepages icon x

datanami | Key Questions to Ask of Your Scientific Data Platform for Single Cell Analysis

The idea of precision medicine – delivering the right drug treatment to the right patient at the right time and at the right dose – underpins current thinking in pharma R&D. by Zach Pitluk

whitepages icon x

Foundational partnership with Paradigm4 enables Alnylam Pharmaceuticals to rapidly accelerate RNAi- based drug target discovery

25th October 2022: Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline. Using Paradigm4’s cloud-based scientific analytics platform and data from the UK Biobank, Alnylam has identified

whitepages icon x

Bio-IT World || Lessons From the Recent HCA 2022 General Meeting: Applying Single-Cell Data to Clinical Decision Making

The recent Human Cell Atlas (HCA) 2022 General Meeting, hosted in Vienna, Austria, provided a great opportunity for me to catch up on progress towards the HCA’s goal of mapping every cell type in the human body. I also got the chance to hear presentations that either highlighted new insights